BioAtla Return on Equity

BioAtla (BCAB) currently reports a ROE of 25.75%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore BioAtla's ROE history and peer comparisons.

BioAtla's ROE of 25.75% is higher than the Healthcare sector average of 11.15%. That is roughly 130.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but BioAtla's current 25.75% should be judged against Healthcare norms (sector average: 11.15%) and against BCAB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 25.75%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for BioAtla, and consider following BCAB for alerts when major investors trade the stock.

BioAtla is classified in the Healthcare sector. On ROE, it currently shows 25.75% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCAB with unrelated industries.